Author: Jerry Matczak

Community Manager for the Lilly Clinical Open Innovation team. If you can place the lyrics "Gerela's Gorrilas are here for the show," know who created the Terrible Towel and smile broadly at memories of the Immaculate Reception you know a little about me.

All Posts by Jerry Matczak

Welcome Gary Takher! 4

LCOI • Tags: , , , , ,

Gary Takher is a recent addition to the Lilly Clinical Open Innovation team. He is part of Lilly’s Visiting Scientist Fellowship Program, which is designed to allow recent doctoral graduates the ability to learn and apply their experiences in focused areas within the organization.

Gary brings scientific and business knowledge with him to the team, as well as some valuable new perspectives. Over the past 4 years, Gary has constructed healthcare models that seek to improve patient health outcomes while lessening their overall healthcare cost burden. Gary has a BS in Biochemistry from the University of California, Los Angeles (UCLA) and recently earned his executive MBA from California State University, Sacramento and his Pharm.D from California Northstate University. With an entrepreneurial spirit, Gary’s passion is to optimize patients’ health outcomes by coupling genuine engagement with expedient decision-making.

You have a unique educational background with a BS in Biochemistry, an MBA, and a Pharm. D. What motivated you to pursue this education path? More…

Poll: What Clinical Drug Development Processes Should Be Opened Up? 3

LCOI • Tags: , ,

Open Innovation can be applied in many ways.   And Open Innovation in drug development is rare and unfamiliar.  So, in an attempt to help clarify what we mean by Clinical Open Innovation, we’ll get down to some examples.

We believe there are many clinical development processes that should not be considered competitive and do not directly impact the pharma intellectual property model. By opening them up it can help patients and drug developers.  Our approach is to leverage open and free knowledge generation to do so.

You may ask, what are some processes to think about? Here are a few: More…

A Patient View of Clinical Collections 1

LCOI • Tags: , , ,

Today we’re going to take a look at the Clinical Collections tool from the point of view of the patient.  Patients (as well as their family members) have a unique, personal perspective on disease, and many quickly become experts in their own right. They tend to put in a lot of hours on- and off-line, reading research materials and talking to other people to get answers and help.

Where Clinical Collections helps all kinds of researchers – physicians, scientists, and clinicians – pull together relevant data for their work, our team has found that the tool is also valuable for patients and others who are doing research of their own.  Take a look as we walk through Clinical Collections with the eyes of two patients, one who simply wants to pull together relevant information, and one who is looking to be involved in a clinical trial close to their home.
More…

LCOI-API Series: Introducing the Lilly Clinical Open Innovation API 2

LCOI • Tags: , , , ,

This is the first in a series of blog posts introducing the LCOI-API.  We’ll discuss it’s purpose and value, and share how it can be used by developers to create solutions in the spirit of clinical open innovation.

We are proud to publish version 1.0 of the LCOI-API and share it with you.

For the non-techie among us, the acronym stands for Application Programming Interface. Simply put, an API allows software to communicate with each other.  A good API makes it easier to improve or create new applications by providing functionality and data. More…